Abstract In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes
Given that appetite and weight control will be key targets for an oral formulation, it is fortuitous that it is the stimulation of vagal afferents that has a direct impact on satiety effects of GLP1-RAs ( Statements Data availability statement The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author
Clinical trials show that semaglutide recipients experience an average weight reduction of 10-15% of their starting body weight over 68 weeks, with higher doses generally producing greater results
Ann Microbiol 69:13871395
Johnson M, Koukoulis G, Matsumoto K, Nakamura T, Iyer A (Jun 1993)
National Center for Biotechnology Information (NCBI)